Detalhe da pesquisa
1.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer
; 129(15): 2308-2320, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078412
2.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
3.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
4.
Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Immunol Invest
; 51(8): 2176-2214, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259611
5.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
6.
MRD in AML: who, what, when, where, and how?
Blood
; 143(4): 296-298, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270942
7.
Treating acute myeloid leukemia in the modern era: A primer.
Cancer
; 126(21): 4668-4677, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767757
8.
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Invest New Drugs
; 38(2): 340-349, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31102119
9.
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Am J Hematol
; 95(12): 1457-1465, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32777116
10.
Progress in the problem of relapsed or refractory acute myeloid leukemia.
Curr Opin Hematol
; 26(2): 88-95, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30640734
11.
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
Haematologica
; 103(6): 982-987, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567781
12.
Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Hematol Oncol
; 40(1): 115-118, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34713477
13.
Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Am J Hematol
; 96(7): E223-E225, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761147
14.
Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
Ann Hematol
; 99(6): 1411-1413, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32377815
15.
Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG).
J Geriatr Oncol
; 15(2): 101626, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37741771
16.
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
J Hematol Oncol
; 17(1): 28, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702786
17.
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/ß-catenin signaling.
Exp Hematol Oncol
; 13(1): 27, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438856
18.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Blood Adv
; 8(2): 429-440, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871309
19.
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.
JCI Insight
; 9(8)2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38646934
20.
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Leukemia
; 38(1): 45-57, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38017103